MingMed Biotechnology presenta datos positivos de QA102 oral para la degeneración macular asociada a la edad

Phase 2positiveQA102Positive

AI Analysis

Summary

MingMed Biotechnology presented positive Phase II data for QA102 oral formulation for intermediate age-related macular degeneration at the ARVO 2026 conference. The candidate demonstrated positive efficacy results in this indication.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Phase II data for oral QA102 presented at ARVO 2026

Importance:6/10

Sentiment:

0.70

Phase 2 dataophthalmologyAMDoral formulationconference presentation

Related Companies

$CFOO

Read the original article

Published by PR Newswire Biotech on May 6, 2026 12:28 AM

Read Original